Want to see LLY full AI Analyst Report?

Eli Lilly & Co (LLY) Stock Forecast & Price Target

22,522 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

20 Buy

2 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,290.79

▲(39.24% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,290.79 with a high forecast of $1,500.00 and a low forecast of $1,135.00. The average price target represents a 39.24% change from the last price of $927.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"728":"$728","1501":"$1,501","921.25":"$921.3","1114.5":"$1,114.5","1307.75":"$1,307.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1290.7894736842104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.14K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[728,921.25,1114.5,1307.75,1501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1114.3384615384616,1146.4769230769232,1178.6153846153848,1210.753846153846,1242.8923076923077,1275.0307692307692,1307.1692307692308,1339.3076923076924,1371.4461538461537,1403.5846153846155,1435.7230769230769,1467.8615384615384,{"y":1500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1098.2453441295547,1114.2906882591094,1130.336032388664,1146.3813765182185,1162.4267206477732,1178.472064777328,1194.5174089068826,1210.5627530364372,1226.608097165992,1242.6534412955466,1258.698785425101,1274.7441295546557,{"y":1290.7894736842104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1086.2615384615385,1090.323076923077,1094.3846153846155,1098.446153846154,1102.5076923076924,1106.569230769231,1110.6307692307691,1114.6923076923076,1118.753846153846,1122.8153846153846,1126.876923076923,1130.9384615384615,{"y":1135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":741.871,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":770.449,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":756.975,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 79,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":729.031,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":821.422,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":858.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1054.312,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1071.045,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1040.599,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1016.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":952.879,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.674,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1082.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,500

Average Price Target$1,291

Lowest Price Target$1,135

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Akash Tewari

Jefferies

$1,350

Buy

45.63%

Upside

Reiterated

06/29/26

Emily Field

Barclays

$1,400

Buy

51.02%

Upside

Reiterated

06/29/26

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

$1,300

Buy

40.23%

Upside

Reiterated

06/26/26

Bernstein Keeps Their Buy Rating on Eli Lilly & Co (LLY)

David Risinger

Leerink Partners

$1,119→$1,232

Buy

32.90%

Upside

Reiterated

06/25/26

Eli Lilly price target raised to $1,232 from $1,119 at LeerinkEli Lilly price target raised to $1,232 from $1,119 at Leerink

Kerry Holford

Berenberg Bank

$1,050→$1,135

Hold

22.43%

Upside

Reiterated

06/22/26

Eli Lilly price target raised to $1,135 from $1,050 at BerenbergEli Lilly price target raised to $1,135 from $1,050 at Berenberg

Geoff Meacham

Citi

$1,500

Buy

61.81%

Upside

Reiterated

06/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Evan Seigerman

BMO Capital

$1,300

Buy

40.23%

Upside

Reiterated

06/14/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

06/09/26

Analyst Reaffirms Buy on Eli Lilly, Citing Durable Obesity Leadership and Multi‑Year Incretin Pipeline Upside

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

06/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)

Terence Flynn

Morgan Stanley

$1,344

Buy

44.98%

Upside

Reiterated

06/08/26

Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

$1,260→$1,283

Buy

38.40%

Upside

Assigned

06/08/26

Buy Rating Reiterated on Eli Lilly as Obesity Pipeline Strength Justifies Unchanged $1,283 Price Target

Mohit Bansal

Wells Fargo

$1,280

Buy

38.08%

Upside

Reiterated

05/27/26

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)

Jason Gerberry

Bank of America Securities

$1,133→$1,251

Buy

34.95%

Upside

Reiterated

05/26/26

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX)

Trung Huynh

RBC Capital

$1,250

Buy

34.84%

Upside

Reiterated

05/21/26

Eli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC CapitalEli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC Capital

Alexandria Hammond

Wolfe Research

$1,325→$1,350

Buy

45.63%

Upside

Reiterated

05/21/26

Eli Lilly 'sets new bar' with retatrutide trial results, says Wolfe ResearchEli Lilly 'sets new bar' with retatrutide trial results, says Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Akash Tewari

Jefferies

$1,350

Buy

45.63%

Upside

Reiterated

06/29/26

Emily Field

Barclays

$1,400

Buy

51.02%

Upside

Reiterated

06/29/26

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

$1,300

Buy

40.23%

Upside

Reiterated

06/26/26

Bernstein Keeps Their Buy Rating on Eli Lilly & Co (LLY)

David Risinger

Leerink Partners

$1,119→$1,232

Buy

32.90%

Upside

Reiterated

06/25/26

Eli Lilly price target raised to $1,232 from $1,119 at LeerinkEli Lilly price target raised to $1,232 from $1,119 at Leerink

Kerry Holford

Berenberg Bank

$1,050→$1,135

Hold

22.43%

Upside

Reiterated

06/22/26

Eli Lilly price target raised to $1,135 from $1,050 at BerenbergEli Lilly price target raised to $1,135 from $1,050 at Berenberg

Geoff Meacham

Citi

$1,500

Buy

61.81%

Upside

Reiterated

06/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Evan Seigerman

BMO Capital

$1,300

Buy

40.23%

Upside

Reiterated

06/14/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

06/09/26

Analyst Reaffirms Buy on Eli Lilly, Citing Durable Obesity Leadership and Multi‑Year Incretin Pipeline Upside

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

06/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)

Terence Flynn

Morgan Stanley

$1,344

Buy

44.98%

Upside

Reiterated

06/08/26

Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

$1,260→$1,283

Buy

38.40%

Upside

Assigned

06/08/26

Buy Rating Reiterated on Eli Lilly as Obesity Pipeline Strength Justifies Unchanged $1,283 Price Target

Mohit Bansal

Wells Fargo

$1,280

Buy

38.08%

Upside

Reiterated

05/27/26

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)

Jason Gerberry

Bank of America Securities

$1,133→$1,251

Buy

34.95%

Upside

Reiterated

05/26/26

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX)

Trung Huynh

RBC Capital

$1,250

Buy

34.84%

Upside

Reiterated

05/21/26

Eli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC CapitalEli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC Capital

Alexandria Hammond

Wolfe Research

$1,325→$1,350

Buy

45.63%

Upside

Reiterated

05/21/26

Eli Lilly 'sets new bar' with retatrutide trial results, says Wolfe ResearchEli Lilly 'sets new bar' with retatrutide trial results, says Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Louise ChenScotiabank

Success Rate

28/37 ratings generated profit

Average Return

+9.18%

Copying Louise Chen's trades and holding each position for 3 Months would result in 75.68% of your transactions generating a profit, with an average return of +9.18% per trade.

1 Year

Geoff MeachamCiti

Success Rate

42/43 ratings generated profit

Average Return

+44.67%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.67% of your transactions generating a profit, with an average return of +44.67% per trade.

2 Years

Carter GouldCantor Fitzgerald

Success Rate

40/40 ratings generated profit

Average Return

+80.11%

Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +80.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 87 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,290.79.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $8.80 with a range of $8.16 to $9.36. The previous quarter’s EPS was $8.55. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $20.48B with a range of $20.08B to $21.20B. The previous quarter’s sales results were $19.80B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 1,290.79.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly And Company has 39.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly And Company has a consensus rating of Strong Buy which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.

What is Eli Lilly And Company’s price target?

The average price target for Eli Lilly And Company is 1,290.79. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,500.00 ,the lowest forecast is $1,135.00. The average price target represents 39.24% Increase from the current price of $927.03.

What do analysts say about Eli Lilly And Company?

Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts